SkinBioTherapeutics PLC (AIM:SBTX), the skin health company, has proposed two additions to the board.
Manprit Singh Randhawa has been announced as full time chief financial officer (CFO), taking over from the company’s current part-time CFO, Doug Quinn, while Danielle Bekker has been nominated as a non-executive director (NED), subject to the completion of normal regulatory due diligence.
Manprit Singh Randhawa most recently worked as CFO at the leading educational technology firm, Juniper Education Group.
Bekker brings experience in directly-to-consumer marketing, including a focus on the use of influencers and digital media in the fast-moving consumer goods (FMCG) space.
"We have changed the CFO position from part-time to full-time role to reflect the new commercial path of the business. We are delighted to welcome Manprit to SkinBioTherapeutics at this exciting commercial stage of the company's development, following the launch of AxisBiotix-Ps. His financial expertise in scale-up environments at both private and AIM-listed companies makes him an excellent fit for the full-time CFO role and we are looking forward to him joining the team," said Martin Hunt, the chair of SkinBioTherapeutics.
“We also look forward to welcoming Danielle to the board. We have deliberately chosen a NED with FMCG experience since this brings a fresh outlook and varied experience, as well as her extensive network, to our commercialisation plans. She has considerable skills in how to sell to consumers using digital marketing, including influencers, which we believe will be invaluable as we accelerate the sales of AxisBiotix-Ps as well as driving our long-term ambitions of launching into other consumer areas," Hunt added.